Breast cancer is the most common malignancy in women worldwide and one of the leading causes of cancer death . Triple negative breast cancer is defined by the lack of estrogen and progesterone receptors as well as an absence of HER2 (human epidermal growth factor receptor 2) amplification. Because of the lack of specific targeted therapy, 30–40% of patients with early-stage TNBC develop metastatic disease and succumb to the cancer, despite receiving standard multi-agent adjuvant chemotherapy  .Both molecular and immunohistochemical analyses demonstrate that a subset of TNBC expresses androgen resistance [ AR ] . AR dependency has also been suggested in a subset of ER-negative, AR-positive breast cancers. Recently, numerous preclinical studies have validated the use of AR modulation in limiting cell proliferation, growth on soft agar, and tumor initiation in vivo and there are ongoing clinical trials evaluating the efficacy of AR antagonists in ER- negative breast cancer for bicalutamide, enzalutamide.